2024 ICD-10-CM Diagnosis Code T36.8X5D

Adverse effect of other systemic antibiotics, subsequent encounter

ICD-10-CM Code:
T36.8X5D
ICD-10 Code for:
Adverse effect of other systemic antibiotics, subs encntr
Is Billable?
Yes - Valid for Submission
Chronic Condition Indicator: [1]
Not chronic
Code Navigator:

Code Classification

  • Injury, poisoning and certain other consequences of external causes
    (S00–T88)
    • Poisoning by, adverse effect of and underdosing of drugs, medicaments and biological substances
      (T36-T50)
      • Poisoning by, adverse effect of and underdosing of systemic antibiotics
        (T36)

T36.8X5D is a billable diagnosis code used to specify a medical diagnosis of adverse effect of other systemic antibiotics, subsequent encounter. The code is valid during the current fiscal year for the submission of HIPAA-covered transactions from October 01, 2023 through September 30, 2024. The code is exempt from present on admission (POA) reporting for inpatient admissions to general acute care hospitals.

This code describes a circumstance which influences the patient's health status but not a current illness or injury. The code is unacceptable as a principal diagnosis.

T36.8X5D is a subsequent encounter code, includes a 7th character and should be used after the patient has completed active treatment for a condition like adverse effect of other systemic antibiotics. According to ICD-10-CM Guidelines a "subsequent encounter" occurs when the patient is receiving routine care for the condition during the healing or recovery phase of treatment. Subsequent diagnosis codes are appropriate during the recovery phase, no matter how many times the patient has seen the provider for this condition. If the provider needs to adjust the patient's care plan due to a setback or other complication, the encounter becomes active again.

Approximate Synonyms

The following clinical terms are approximate synonyms or lay terms that might be used to identify the correct diagnosis code:

  • 4-quinolones adverse reaction
  • Acrosoxacin adverse reaction
  • Adverse reaction to sulfamethoxazole and/or trimethoprim
  • Antituberculous drug adverse reaction
  • Capreomycin adverse reaction
  • Ciprofloxacin adverse reaction
  • Ciprofloxacin corneal deposits
  • Clindamycin adverse reaction
  • Colistin adverse reaction
  • Drug-induced corneal epithlelial deposit
  • Drug-induced disorder of cornea
  • Enoxacin adverse reaction
  • Erythroderma caused by drug
  • Erythroderma caused by vancomycin
  • Fosfomycin adverse reaction
  • Fusidic acid adverse reaction
  • Lincomycin adverse reaction
  • Norfloxacin adverse reaction
  • Ofloxacin adverse reaction
  • Polymyxin B adverse reaction
  • Polymyxins adverse reaction
  • Teicoplanin adverse reaction
  • Temafloxacin adverse reaction
  • Vancomycin adverse reaction

Clinical Classification

Clinical Information

  • Capreomycin

    cyclic peptide antibiotic similar to viomycin. it is produced by streptomyces capreolus.
  • Ciprofloxacin

    a broad-spectrum antimicrobial carboxyfluoroquinoline.
  • Clindamycin

    an antibacterial agent that is a semisynthetic analog of lincomycin.
  • Colistin

    cyclic polypeptide antibiotic from bacillus colistinus. it is composed of polymyxins e1 and e2 (or colistins a, b, and c) which act as detergents on cell membranes. colistin is less toxic than polymyxin b, but otherwise similar; the methanesulfonate is used orally.
  • Enoxacin

    a broad-spectrum 6-fluoronaphthyridinone antibacterial agent that is structurally related to nalidixic acid.
  • Enviomycin

    cyclic basic peptide related to viomycin. it is isolated from an induced mutant of streptomyces griseoverticillatus var. tuberacticus and acts as an antitubercular agent with less ototoxicity than tuberactinomycin.
  • Fleroxacin

    a broad-spectrum antimicrobial fluoroquinolone. the drug strongly inhibits the dna-supercoiling activity of dna gyrase.
  • Fosfomycin

    an antibiotic produced by streptomyces fradiae.
  • Fusidic Acid

    an antibiotic isolated from the fermentation broth of fusidium coccineum. (from merck index, 11th ed). it acts by inhibiting translocation during protein synthesis.
  • Lincomycin

    an antibiotic produced by streptomyces lincolnensis var. lincolnensis. it has been used in the treatment of staphylococcal, streptococcal, and bacteroides fragilis infections.
  • Norfloxacin

    a synthetic fluoroquinolone (fluoroquinolones) with broad-spectrum antibacterial activity against most gram-negative and gram-positive bacteria. norfloxacin inhibits bacterial dna gyrase.
  • Levofloxacin

    the l-isomer of ofloxacin.
  • Ofloxacin

    a synthetic fluoroquinolone antibacterial agent that inhibits the supercoiling activity of bacterial dna gyrase, halting dna replication.
  • Ristocetin

    an antibiotic mixture of two components, a and b, obtained from nocardia lurida (or the same substance produced by any other means). it is no longer used clinically because of its toxicity. it causes platelet agglutination and blood coagulation and is used to assay those functions in vitro.
  • von Willebrand Factor

    a high-molecular-weight plasma protein, produced by endothelial cells and megakaryocytes, that is part of the factor viii/von willebrand factor complex. the von willebrand factor has receptors for collagen, platelets, and ristocetin activity as well as the immunologically distinct antigenic determinants. it functions in adhesion of platelets to collagen and hemostatic plug formation. the prolonged bleeding time in von willebrand diseases is due to the deficiency of this factor.
  • Teicoplanin

    lipoglycopeptide antibiotic from actinoplanes teichomyceticus active against gram-positive bacteria. it consists of five major components each with a different fatty acid moiety.
  • Vancomycin

    antibacterial obtained from streptomyces orientalis. it is a glycopeptide related to ristocetin that inhibits bacterial cell wall assembly and is toxic to kidneys and the inner ear.
  • Vancomycin Resistance

    nonsusceptibility of bacteria to the action of vancomycin, an inhibitor of cell wall synthesis.
  • Vancomycin-Resistant Enterococci

    strains of the genus enterococcus that are resistant to the antibiotic vancomycin. the enterococci become resistant by acquiring plasmids carrying genes for vancomycin resistance.
  • Vancomycin-Resistant Staphylococcus aureus

    isolates of the staphylococcus aureus that are resistant to the antibiotic vancomycin. the s. aureus becomes resistant by acquiring plasmids carrying genes for vancomycin resistance. vancomycin‐intermediate s. aureus has low-level vancomycin resistance requiring an intermediate concentration of vancomycin between sensitive and resistant isolates. these s. aureus with reduced susceptibility to vancomycin and related glycopeptide antibiotics are often seen in healthcare associated infections.
  • Viomycin

    a strongly basic peptide, antibiotic complex from several strains of streptomyces. it is allergenic and toxic to kidneys and the labyrinth. viomycin is used in tuberculosis as several different salts and in combination with other agents.
  • Streptogramin A

    a specific streptogramin group a antibiotic produced by streptomyces graminofaciens and other bacteria.
  • Virginiamycin

    a cyclic polypeptide antibiotic complex from streptomyces virginiae, s. loidensis, s. mitakaensis, s. pristina-spiralis, s. ostreogriseus, and others. it consists of 2 major components, virginiamycin factor m1 and virginiamycin factor s1. it is used to treat infections with gram-positive organisms and as a growth promoter in cattle, swine, and poultry.

Coding Guidelines

When coding an adverse effect of a drug that has been correctly prescribed and properly administered, assign the appropriate code for the nature of the adverse effect followed by the appropriate code for the adverse effect of the drug.

The appropriate 7th character is to be added to each code from block Poisoning by, adverse effect of and underdosing of systemic antibiotics (T36). Use the following options for the aplicable episode of care:

  • A - initial encounter
  • D - subsequent encounter
  • S - sequela

Code Edits

The Medicare Code Editor (MCE) detects and reports errors in the coding of claims data. The following ICD-10-CM Code Edits are applicable to this code:

  • Unacceptable principal diagnosis - There are selected codes that describe a circumstance which influences an individual's health status but not a current illness or injury, or codes that are not specific manifestations but may be due to an underlying cause. These codes are considered unacceptable as a principal diagnosis.

Present on Admission (POA)

T36.8X5D is exempt from POA reporting - The Present on Admission (POA) indicator is used for diagnosis codes included in claims involving inpatient admissions to general acute care hospitals. POA indicators must be reported to CMS on each claim to facilitate the grouping of diagnoses codes into the proper Diagnostic Related Groups (DRG). CMS publishes a listing of specific diagnosis codes that are exempt from the POA reporting requirement. Review other POA exempt codes here.

CMS POA Indicator Options and Definitions

POA IndicatorReason for CodeCMS will pay the CC/MCC DRG?
YDiagnosis was present at time of inpatient admission.YES
NDiagnosis was not present at time of inpatient admission.NO
UDocumentation insufficient to determine if the condition was present at the time of inpatient admission.NO
WClinically undetermined - unable to clinically determine whether the condition was present at the time of inpatient admission.YES
1Unreported/Not used - Exempt from POA reporting. NO

Convert T36.8X5D to ICD-9-CM

  • ICD-9-CM Code: V58.89 - Other specfied aftercare
    Approximate Flag - The approximate mapping means there is not an exact match between the ICD-10 and ICD-9 codes and the mapped code is not a precise representation of the original code.

Table of Drugs and Chemicals

The parent code T36.8X5 of the current diagnosis code is referenced in the Table of Drugs and Chemicals, this table contains a classification of drugs, industrial solvents, corrosive gases, noxious plants, pesticides, and other toxic agents.

According to ICD-10-CM coding guidelines it is advised to do not code directly from the Table of Drugs and Chemicals, instead always refer back to the Tabular List when doing the initial coding. Each substance in the table is assigned a code according to the poisoning classification and external causes of adverse effects. It is important to use as many codes as necessary to specify all reported drugs, medicinal or chemical substances. If the same diagnosis code describes the causative agent for more than one adverse reaction, poisoning, toxic effect or underdosing, utilize the code only once.

Substance Poisoning
Accidental
(unintentional)
Poisoning
Accidental
(self-harm)
Poisoning
Assault
Poisoning
Undetermined
Adverse
effect
Underdosing
AerosporinT36.8X1T36.8X2T36.8X3T36.8X4T36.8X5T36.8X6
Aerosporin
  »ENT agent
T36.8X1T36.8X2T36.8X3T36.8X4T36.8X5T36.8X6
Aerosporin
  »ophthalmic preparation
T36.8X1T36.8X2T36.8X3T36.8X4T36.8X5T36.8X6
Aerosporin
  »topical NEC
T36.8X1T36.8X2T36.8X3T36.8X4T36.8X5T36.8X6
AlbamycinT36.8X1T36.8X2T36.8X3T36.8X4T36.8X5T36.8X6
AmfomycinT36.8X1T36.8X2T36.8X3T36.8X4T36.8X5T36.8X6
AmphomycinT36.8X1T36.8X2T36.8X3T36.8X4T36.8X5T36.8X6
BetamicinT36.8X1T36.8X2T36.8X3T36.8X4T36.8X5T36.8X6
CapreomycinT36.8X1T36.8X2T36.8X3T36.8X4T36.8X5T36.8X6
CarbomycinT36.8X1T36.8X2T36.8X3T36.8X4T36.8X5T36.8X6
CathomycinT36.8X1T36.8X2T36.8X3T36.8X4T36.8X5T36.8X6
CiprofloxacinT36.8X1T36.8X2T36.8X3T36.8X4T36.8X5T36.8X6
ClindamycinT36.8X1T36.8X2T36.8X3T36.8X4T36.8X5T36.8X6
ColimycinT36.8X1T36.8X2T36.8X3T36.8X4T36.8X5T36.8X6
ColistimethateT36.8X1T36.8X2T36.8X3T36.8X4T36.8X5T36.8X6
ColistinT36.8X1T36.8X2T36.8X3T36.8X4T36.8X5T36.8X6
Colistin
  »sulfate (eye preparation)
T36.8X1T36.8X2T36.8X3T36.8X4T36.8X5T36.8X6
Co-trimoxazoleT36.8X1T36.8X2T36.8X3T36.8X4T36.8X5T36.8X6
EnoxacinT36.8X1T36.8X2T36.8X3T36.8X4T36.8X5T36.8X6
EnviomycinT36.8X1T36.8X2T36.8X3T36.8X4T36.8X5T36.8X6
FleroxacinT36.8X1T36.8X2T36.8X3T36.8X4T36.8X5T36.8X6
FosfomycinT36.8X1T36.8X2T36.8X3T36.8X4T36.8X5T36.8X6
FugillinT36.8X1T36.8X2T36.8X3T36.8X4T36.8X5T36.8X6
FumadilT36.8X1T36.8X2T36.8X3T36.8X4T36.8X5T36.8X6
FumagillinT36.8X1T36.8X2T36.8X3T36.8X4T36.8X5T36.8X6
FusafungineT36.8X1T36.8X2T36.8X3T36.8X4T36.8X5T36.8X6
Fusidate (ethanolamine) (sodium)T36.8X1T36.8X2T36.8X3T36.8X4T36.8X5T36.8X6
Fusidic acidT36.8X1T36.8X2T36.8X3T36.8X4T36.8X5T36.8X6
LincomycinT36.8X1T36.8X2T36.8X3T36.8X4T36.8X5T36.8X6
MagnamycinT36.8X1T36.8X2T36.8X3T36.8X4T36.8X5T36.8X6
MycitracinT36.8X1T36.8X2T36.8X3T36.8X4T36.8X5T36.8X6
Mycitracin
  »ophthalmic preparation
T36.8X1T36.8X2T36.8X3T36.8X4T36.8X5T36.8X6
NeosporinT36.8X1T36.8X2T36.8X3T36.8X4T36.8X5T36.8X6
Neosporin
  »ENT agent
T36.8X1T36.8X2T36.8X3T36.8X4T36.8X5T36.8X6
Neosporin
  »opthalmic preparation
T36.8X1T36.8X2T36.8X3T36.8X4T36.8X5T36.8X6
Neosporin
  »topical NEC
T36.8X1T36.8X2T36.8X3T36.8X4T36.8X5T36.8X6
NorfloxacinT36.8X1T36.8X2T36.8X3T36.8X4T36.8X5T36.8X6
OfloxacinT36.8X1T36.8X2T36.8X3T36.8X4T36.8X5T36.8X6
PolymyxinT36.8X1T36.8X2T36.8X3T36.8X4T36.8X5T36.8X6
Polymyxin
  »B
T36.8X1T36.8X2T36.8X3T36.8X4T36.8X5T36.8X6
Polymyxin
  »B
    »ENT agent
T36.8X1T36.8X2T36.8X3T36.8X4T36.8X5T36.8X6
Polymyxin
  »B
    »ophthalmic preparation
T36.8X1T36.8X2T36.8X3T36.8X4T36.8X5T36.8X6
Polymyxin
  »B
    »topical NEC
T36.8X1T36.8X2T36.8X3T36.8X4T36.8X5T36.8X6
Polymyxin
  »E sulfate (eye preparation)
T36.8X1T36.8X2T36.8X3T36.8X4T36.8X5T36.8X6
RistocetinT36.8X1T36.8X2T36.8X3T36.8X4T36.8X5T36.8X6
SulfomyxinT36.8X1T36.8X2T36.8X3T36.8X4T36.8X5T36.8X6
TeicoplaninT36.8X1T36.8X2T36.8X3T36.8X4T36.8X5T36.8X6
VancomycinT36.8X1T36.8X2T36.8X3T36.8X4T36.8X5T36.8X6
ViomycinT36.8X1T36.8X2T36.8X3T36.8X4T36.8X5T36.8X6
VirginiamycinT36.8X1T36.8X2T36.8X3T36.8X4T36.8X5T36.8X6

Patient Education


Drug Reactions

Most of the time, medicines make our lives better. They reduce aches and pains, fight infections, and control problems such as high blood pressure or diabetes. But medicines can also cause unwanted reactions, such as drug interactions, side effects, and allergies.

What is a drug interaction?

A drug interaction is a change in the way a drug acts in the body when taken with certain other drugs, foods, or supplements or when taken while you have certain medical conditions. Examples include:

  • Two drugs, such as aspirin and blood thinners
  • Drugs and food, such as statins and grapefruit
  • Drugs and supplements, such as gingko and blood thinners
  • Drugs and medical conditions, such as aspirin and peptic ulcers

Interactions could cause a drug to be more or less effective, cause side effects, or change the way one or both drugs work.

What are side effects?

Side effects are unwanted, usually unpleasant, effects caused by medicines. Most are mild, such as a stomachache, dry mouth, or drowsiness, and go away after you stop taking the medicine. Others can be more serious. Sometimes a drug can interact with a disease that you have and cause a side effect. For example, if you have a heart condition, certain decongestants can cause you to have a rapid heartbeat.

What are drug allergies?

Drug allergies are another type of reaction. They can range from mild to life-threatening. Skin reactions, such as hives and rashes, are the most common type. Anaphylaxis, a serious allergic reaction, is less common.

How can I stay safe when taking medicines?

When you start a new prescription or over-the-counter medicine, make sure you understand how to take it correctly. Know which other medicines, foods, and supplements you need to avoid. Always talk to your health care provider or pharmacist if you have questions about your medicines.


[Learn More in MedlinePlus]

Code History

  • FY 2024 - No Change, effective from 10/1/2023 through 9/30/2024
  • FY 2023 - No Change, effective from 10/1/2022 through 9/30/2023
  • FY 2022 - No Change, effective from 10/1/2021 through 9/30/2022
  • FY 2021 - No Change, effective from 10/1/2020 through 9/30/2021
  • FY 2020 - No Change, effective from 10/1/2019 through 9/30/2020
  • FY 2019 - No Change, effective from 10/1/2018 through 9/30/2019
  • FY 2018 - No Change, effective from 10/1/2017 through 9/30/2018
  • FY 2017 - No Change, effective from 10/1/2016 through 9/30/2017
  • FY 2016 - New Code, effective from 10/1/2015 through 9/30/2016. This was the first year ICD-10-CM was implemented into the HIPAA code set.

Footnotes

[1] Not chronic - A diagnosis code that does not fit the criteria for chronic condition (duration, ongoing medical treatment, and limitations) is considered not chronic. Some codes designated as not chronic are acute conditions. Other diagnosis codes that indicate a possible chronic condition, but for which the duration of the illness is not specified in the code description (i.e., we do not know the condition has lasted 12 months or longer) also are considered not chronic.